NCT05289947CompletedPhase 2
MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of MLC1501 in Patients With Stroke
Source: ClinicalTrials.gov · Last updated 9 Dec 2025
Brief summary (registry, in English)
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for 24 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 303 (actual)
- First submitted
- 11 Mar 2022
- Start date
- 21 Jul 2023
- Primary completion date
- 18 Jul 2025
- Lead sponsor
- Moleac Pte Ltd.
- Diseases
- Stroke
- NCT number
- NCT05289947
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 303
- From 21 Jul 2023 to the primary completion date, 18 Jul 2025
- 11 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another investigational drug or device trial within the past 30 days.
- Women who are pregnant or wish to continue breastfeeding while in the study. Women of child-bearing potential may be included if they agree to strict abstinence or use of effective contraception, except systemically acting hormonal contraceptives. Hormone replacement therapy in menopausal/post-menopausal or surgically sterilized women is also not allowed while in the study.
Other illness
- Pre-stroke modified Rankin score of \>1.
- Any known food allergy or hypersensitivity to Astragalus membranaceus, Ligusticum chuanxiong, Polygala tenuifolia, Angelica sinensis, or members of the Fabaceae/Leguminosae family (e.g., legume, pea, bean), Polygalaceae family (e.g., milkwort, snakeroot), Apiaceae/Umbelliferae family (e.g., anise, caraway, carrot, celery, dill, parsley, parsnip), or Quillaja bark (soapbark).
- Evidence of advanced medical condition that would affect study assessment and follow-up, such as cancer, renal failure, liver cirrhosis, severe dementia, or psychosis.
- Any other medical or psychiatric or cognitive condition which, in the study investigator's opinion, may jeopardize the patient by his/her participation in this study, may hamper his/her ability to complete procedures required in the study, affect study assessment and follow-up, or affect the validity of the study results.
Other
- Contraindication to any of the study procedures.
- Patients who became medically unstable within 24 hours after intravenous or endovascular thrombolysis or thrombectomy.
- Intake of any herbal or traditional medicine within the past 30 days.
- Intake of warfarin in the past one week or expected to be on warfarin while in the study.
- Evidence of other significant non-ischemic brain lesion which could affect long-term function or disability.
Who the study is looking for
- Male or female.
- ≥18 years old or legal age as per country requirement
- Diagnosed with acute ischemic stroke with compatible brain imaging findings between 2 days to 10 days (inclusive) prior to inclusion.
- NIHSS total score of 8 to 18 (inclusive) at the time of inclusion with a combined score of at least 3 on the NIHSS motor items 5A or 5B and/or 6A or 6B.
- A candidate for active rehabilitation in the opinion of the treating physician.
- Able to comply with the requirements of the protocol and provide written informed consent by patient or legal representative before any study-specific procedure is performed.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Baguio General Hospital and Medical Center Coordinator of this site? Confirm its status | Baguio City | Philippines | Unknown status |
| Metro Davao Medical And Research Center Coordinator of this site? Confirm its status | Davao City | Philippines | Unknown status |
| West Visayas State University Medical Center Coordinator of this site? Confirm its status | Iloilo City | Philippines | Unknown status |
| Jose R. Reyes Memorial Medical Center Coordinator of this site? Confirm its status | Manila | Philippines | Unknown status |
| Manila Doctors Hospita Coordinator of this site? Confirm its status | Manila | Philippines | Unknown status |
| University of Santo Tomas Hospital Coordinator of this site? Confirm its status | Manila | Philippines | Unknown status |
| Quirino Memorial Medical Center Coordinator of this site? Confirm its status | Manila | Philippines | Unknown status |
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Raffles Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| Changi General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| National Neuroscience Institute (NNI) @ Tan Tock Seng Hospital (TTSH) Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.